Earlier on Friday, Novo Nordisk A/S NVO introduced headline outcomes from a part 2a medical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist.
After 16 weeks of remedy, folks handled with a once-daily 10 mg dose of monlunabant achieved a weight lack of 7.1 kg in comparison with a discount of 0.7 kg with a placebo.
In all probability, the buyers are reacting to the restricted further weight reduction seen at greater doses.
In March, Novo Nordisk shared monlunabant replace throughout its Capital Markets Day 2024.
In Section 1, monlunabant produced a statistically vital imply weight lack of 3.5 kg (3.3%) in comparison with 0.6 kg (0.5%) with placebo at day 28.
Corbus Prescribed drugs Holdings Inc. CRBP and Skye Bioscience Inc. SKYE shares plunged in response to the information.
All three firms are creating weight reduction medication that make use of a mechanism of motion, peripheral CB1 inhibition.
Corbus Prescribed drugs’ investigational CRB-913, additionally a CB1 inverse agonist, is within the preclinical part. Human trials are anticipated to start out within the first quarter of 2025.
Analyst reactions:
- Wedbush maintains Corbus Prescribed drugs with an Outperform score and lowered the worth goal from $85 to $51.
- B. Riley Securities maintains Corbus with a Purchase and lowered the worth goal from $85 to $40.
Skye is conducting a Section 2 trial in weight problems for nimacimab, a unfavourable allosteric modulating antibody that peripherally inhibits CB1.
This research can also be assessing the mix of nimacimab and Novo Nordisk’s Wegovy (semaglutide). Skye expects interim and topline knowledge from its Section 2 research in 2025.
Jefferies analyst notes that whereas expectations for Corbus’ asset have been tempered, key uncertainties persist, making it tough to attract agency conclusions. That is notably true as Novo Nordisk advances its weight problems candidate. Extra insights from long-term open-label extension knowledge, anticipated in late October, might present extra readability.
Worth Motion: SKYE inventory is down 41% at $3.24, and CRBP inventory is down 59.4% at $21.00 finally verify Friday.
Learn Subsequent:
Market Information and Information dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
